慢性粒细胞白血病酪氨酸激酶抑制剂耐药的研究进展  

Progress of tyrosine kinase inhibitor resistance in chronic myeloid leukemia

作　　者：谢梦青 韩梦媛 胡瑞萍[1] 高素君[1] 孙京男[1] Xie Mengqing;Han Mengyuan;Hu Ruiping;Gao Sujun;Sun Jingnan(Department of Hematology,the First Hospital of Jilin University,Changchun 130000,China)

机构地区：[1]吉林大学第一医院血液科,长春130000

出　　处：《白血病．淋巴瘤》2022年第6期374-377,共4页Journal of Leukemia & Lymphoma

摘　　要：慢性粒细胞白血病(CML)是一种骨髓造血干细胞克隆性增殖形成的恶性肿瘤。随着对疾病认识的提高以及新型药物的面市,90%以上的CML患者可以获得长期生存,然而仍有少部分患者耐药。文章分析了应用酪氨酸激酶抑制剂(TKI)治疗CML患者发生耐药的机制,以及ABL激酶区突变的特征。Chronic myeloid leukemia(CML)is a malignant tumor formed by clonal proliferation of bone marrow hematopoietic stem cells.With the improvement of disease awareness and the introduction of new drugs,more than 90%of CML patients can achieve long-term survival.However,a few patients still show drug resistance.This article reviews the mechanism of drug resistance in CML patients treated with tyrosine kinase inhibitor(TKI)and the characteristics of ABL kinase region mutation.

关 键 词：白血病 粒细胞 慢性 耐药机制 ABL激酶区突变 二代测序 

分 类 号：R733.72[医药卫生—肿瘤]